Solid Tumor, Adult Diagnostic Test: BPA-PET imaging

Detailed Description:

Boron Neutron Capture Therapy（BNCT） is an advanced cell-scale binary targeted radiotherapy technology
that combines the advantages of targeted therapy and heavy ion therapy. BNCT provides a neutron source
from a reactor or a medical accelerator. At the same time, the patient needs to be pre-injected with a boron-
containing drug containing a non-radioactive boron 10 isotope. The boron drug enters the body and
accumulates specifically in cancer cells. The patient receives epithermal neutron beam irradiation with high
linear energy transfer (Linear EnergyTransferLET), thereby achieving the effect of killing tumor cells.
Purpose，BNCT has more advantages over conventional radiotherapy, and normal tissue is better preserved
than conventional radiotherapy.

PET imaging is a useful and effective technique to give absolute quantitative and biological distribution data
of BPA in a non-invasive manner, and can add important characteristic parameters such as T/N ratio, SUV
and Kinetic parameters. Given the complexity of BNCT, PET and PET/CT is currently the new standard for
designing patient recruitment: The Methodology of L-18F-BPA PET is an important tool to design clinical trials
, estimate the size of tumor and indicate the concentration ratio of BPA in surrounding normal tissues.
Following this principle, researchers can accurately identify which patients can benefit from BNCT treatment
through the selective accumulation of BPA in individual tumors. PET scans can provide a three-dimensional
map of the boron distribution, which can be used for macroscopic dose calculations in the BNCT conventional
neutron transmission code. Because most of the dose absorbed by living cells (65%) comes from the
10B(n,a)7Li response, the distribution of boron determines the variability of the main absorbed dose in the
treatment plan. As a result, therapeutic schedule will be improved because the boron distribution will greatly
affect the isodose line. Routine calculations provide a wider range of isodose contours, whereas PET
produces contours that more closely approximate the observed clinical results of BNCT.
Study Design Go to 

Study Type  :
Observational

Estimated Enrollment  :
10 participants

Observational Model:
Other

Time Perspective:
Prospective

Official Title:
Fluoride-labeled Boronophenylalanine PET Imaging in Patients With Solid Tumors

Estimated Study Start Date  :

December 25, 2022

Estimated Primary Completion Date  :

August 25, 2023

Estimated Study Completion Date  :

August 25, 2025